Clinical Outcomes of PRX S With Standardized Home Care in Mild-to-Moderate Facial Acne. (PRXS-SINGLE)
Changes in Inflammatory Lesion Count, Tolerability, and Clinical and Instrumental Skin Parameters Following Five PRX S Sessions Combined With Standardized Home Care in Adults With Mild-to-Moderate Facial Acne: A Prospective, Single-Arm, Open-Label Clinical Study.
This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.
The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.
The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.
Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.
All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.
調査の概要
詳細な説明
This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.
The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.
The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.
Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.
All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Anna Deda, PhD
- 電話番号:+48 500 233 457
- メール:adeda@sum.edu.pl
研究場所
-
-
-
Mysłowice、ポーランド、41-400
- AJ Med
-
コンタクト:
- Anna Deda
- 電話番号:+48 500 233 457
- メール:adeda@sum.edu.pl
-
Sosnowiec、ポーランド、41-208
- Department of Practical Cosmetology and Skin Diagnostics
-
コンタクト:
- Anna Deda, PhD
- 電話番号:+48 500 233 457
- メール:adeda@sum.edu.pl
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults aged 18-60 years.
- Mild-to-moderate facial acne vulgaris, defined as Investigator's Global Assessment (IGA) grade 2 or 3, confirmed by a dermatologist at baseline (T0).
- Presence of at least five inflammatory facial acne lesions (papules and/or pustules) at baseline.
- Provision of written informed consent to participate in the study and undergo study-related assessments and documentation.
- No contraindications to the study products and confirmation by a dermatologist that the treatment regimen is clinically appropriate.
- Ability and willingness to attend scheduled study visits and comply with the standardized home skin-care regimen.
- No urgent need for alternative acne treatment that is not provided within the study protocol.
Exclusion Criteria:
- Investigator's Global Assessment (IGA) grade 0, 1, or 4.
- Severe or nodulocystic acne, deep inflammatory lesions, or rapidly progressive acne scarring requiring alternative medical management.
- Pregnancy or breastfeeding.
- Known hypersensitivity to any component of the study products.
- Active herpes simplex infection, other skin infections, wounds, erosions, or burns in the treatment area.
- Active atopic dermatitis, seborrheic dermatitis, or other skin conditions that may interfere with study assessments.
- Skin malignancy or suspicious lesions in the treatment area.
- Medical conditions or concurrent therapies that may significantly increase treatment-related risks or interfere with the interpretation of study outcomes.
- Use of topical retinoids within 30 days before baseline (T0).
- Completion of anti-acne antibiotic therapy less than 3 months before baseline (T0).
- Completion of isotretinoin therapy less than 6 months before baseline (T0).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:PRX S Treatment Combined With Standardized Home Care
Participants will receive five professional PRX S facial treatments at approximately 14-day intervals (days 0, 14, 28, 42, and 56), combined with standardized home skin care consisting of WIQO Nourishing Cream for Normal and Combination Skin applied in the morning and WIQO Balancing Cream applied in the evening. Home care will continue throughout the study, including the follow-up period. Clinical and instrumental assessments will be performed at baseline (T0), after three completed treatments (T1), two weeks after the fifth treatment (T2), and two calendar months after T2 (T3). All participants will receive the same combined regimen, with no placebo or comparator group. |
PRX S is a two-phase topical preparation activated immediately before professional application according to the manufacturer's instructions for use. Participants will undergo five facial treatment sessions at approximately 14-day intervals (days 0, 14, 28, 42, and 56). The procedure will be performed using a standardized protocol appropriate for mild-to-moderate facial acne. The application technique, treatment quantity, and number of layers will follow the approved standard operating procedure and current manufacturer's instructions. All participants will follow a standardized home skin-care regimen using WIQO Nourishing Cream for Normal and Combination Skin and WIQO Balancing Cream. The nourishing cream will be used in the morning and the Balancing Cream in the evening according to the approved study instructions. Home care will continue throughout the treatment and follow-up periods. The regimen will be identical for all participants. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 70
時間枠:Baseline (Day 0) and Day 70 (14 days after the fifth treatment)
|
The outcome is the within-participant change in the total number of inflammatory facial acne lesions (papules and pustules) between baseline (T0) and T2. Lesions will be counted by a trained dermatologist using a standardized facial lesion-counting procedure. The change will be calculated as the T2 lesion count minus the baseline lesion count. A negative value indicates a reduction in inflammatory lesions. |
Baseline (Day 0) and Day 70 (14 days after the fifth treatment)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 42
時間枠:Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).
|
Change in the total number of facial inflammatory acne lesions (papules and pustules), counted by a trained dermatologist. The change is calculated as the Day 42 count minus the baseline count. Negative values indicate improvement. |
Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).
|
|
Change From Baseline in Inflammatory Facial Acne Lesion Count at Follow-up
時間枠:Baseline (Day 0) and T3 (two calendar months after Day 70).
|
Change in the total number of facial inflammatory acne lesions (papules and pustules) between baseline and T3, assessed by a trained dermatologist using standardized lesion counting. Negative values indicate a reduction in inflammatory lesions. |
Baseline (Day 0) and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Facial Comedone Count
時間枠:Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Change in the total number of non-inflammatory facial acne lesions, including open and closed comedones, assessed by a trained dermatologist using standardized lesion counting. The change at each post-baseline visit is calculated as the visit count minus the baseline count. Negative values indicate fewer comedones. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Percentage Reduction From Baseline in Inflammatory Facial Acne Lesion Count
時間枠:Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Percentage reduction in the total number of facial inflammatory acne lesions (papules and pustules), calculated as 100 × (baseline lesion count - post-baseline lesion count) / baseline lesion count. Positive values indicate a reduction in inflammatory lesions. Participants are required to have at least five inflammatory lesions at baseline. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change in Investigator's Global Assessment of Acne Severity
時間枠:Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Acne severity will be assessed by a dermatologist using the static Investigator's Global Assessment (IGA) scale ranging from 0 (clear) to 4 (severe). The distribution of IGA grades and changes in grades from baseline will be reported at each assessment visit. Lower grades indicate less severe acne. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Percentage of Participants Achieving an Investigator's Global Assessment Grade of 0 or 1
時間枠:Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Percentage of evaluable participants achieving an Investigator's Global Assessment (IGA) grade of 0 (clear) or 1 (almost clear) at each post-baseline assessment. IGA is a five-category ordinal scale ranging from 0 (clear) to 4 (severe). |
Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Percentage of Participants Achieving Investigator's Global Assessment Success
時間枠:Day 42, Day 70, and T3 (two calendar months after Day 70).
|
IGA success is defined as achieving an Investigator's Global Assessment grade of 0 (clear) or 1 (almost clear), together with an improvement of at least two grades from baseline. Participants with baseline IGA 2 must achieve grade 0, while participants with baseline IGA 3 may achieve grade 0 or 1. |
Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Facial Skin Sebum Level Measured by Sebumetry
時間枠:Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Facial skin surface sebum will be measured using a sebumeter under standardized measurement conditions. Results will be expressed in micrograms per square centimeter (µg/cm²). Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Stratum Corneum Hydration Measured by Corneometry
時間枠:Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Skin hydration will be assessed using corneometry under standardized measurement conditions. Measurements reflect hydration of the stratum corneum and are expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Skin Elasticity (Cutometer R2 Parameter)
時間枠:Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Skin biomechanical properties will be assessed using a Cutometer. The R2 parameter, representing gross skin elasticity, will be recorded as a dimensionless ratio. Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Dermal Thickness Measured by Skin Ultrasonography
時間枠:Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Dermal thickness will be measured using skin ultrasonography at standardized anatomical measurement sites. Results will be expressed in millimeters (mm). Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Dermal Echogenicity Measured by Skin Ultrasonography
時間枠:Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Dermal echogenicity will be assessed using skin ultrasonography under standardized acquisition conditions. Results will be expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Facial Skin Surface Parameters Assessed by Antera 3D
時間枠:Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Changes in facial skin surface characteristics, including pore-related parameters, skin texture, and surface roughness, will be assessed using the Antera 3D imaging system. Measurements will be performed at standardized anatomical sites and compared with baseline values. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
協力者と研究者
協力者
捜査官
- 主任研究者:Anna Deda, PhD、Medical University of Silesia in Katowice, Poland
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- PRXS-SINGLE-2026-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual participant data underlying the reported study results may be made available to qualified researchers upon reasonable request, subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Data sharing will be considered on a case-by-case basis.
IPD 共有時間枠
De-identified individual participant data may be made available upon reasonable request following publication of the main study results, subject to participant consent, applicable data protection requirements, and sponsor authorization. The duration of availability will be determined in accordance with the sponsor's data retention and sharing policies.
IPD 共有アクセス基準
De-identified individual participant data underlying the published study results may be made available to qualified researchers upon reasonable request. Requests will be reviewed on a case-by-case basis and will be subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Access will be limited to data approved for sharing. Participant-identifiable information and identifiable facial photographs will not be shared without the appropriate consent and legal basis.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。